SCHEMBL9937366

SCHEMBL9937366

c1ccc(-c2nc(Nc3cn[nH]c3)c3ccccc3n2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 11/20 0.68
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
PDE5A O76074 6/20 0.67
TGFBR1 P36897 1/20 0.62
MAPK14 Q16539 1/20 0.62
LMNA P02545 2/20 0.60
TP53 P04637 1/20 0.60
MAPT P10636 1/20 0.60
GAA P10253 1/20 0.60
ALDH1A1 P00352 2/20 0.58
KDM4E B2RXH2 1/20 0.58
POLB P06746 1/20 0.58
HPGD P15428 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
GSK3A P49840 1/20 0.58
GSK3B P49841 1/20 0.58
ABCC1 P33527 1/20 0.58
USP2 O75604 1/20 0.58
CYP1A2 P05177 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1063103 0.82 ABCG2 (1.00) ABCG2MEN1KMT2APDE5ATGFBR1
SCHEMBL31471840 0.82 MEN1 (0.50) ABCG2MEN1KMT2APDE5ALMNA
SCHEMBL4868573 0.78 ABCG2 (1.00) ABCG2MEN1KMT2APDE5ATGFBR1
SCHEMBL14262835 0.77 ABCG2 (0.82) ABCG2MEN1KMT2APDE5ATGFBR1
SCHEMBL412953 0.77 TGFBR1 (1.00) ABCG2MEN1KMT2APDE5ATGFBR1
SCHEMBL31061048 0.77 TGFBR1 (1.00) ABCG2MEN1KMT2APDE5ATGFBR1
SCHEMBL5104273 0.76 ABCG2 (0.78) ABCG2MEN1KMT2APDE5ATGFBR1
SCHEMBL1062324 0.76 PDE5A (1.00) ABCG2MEN1KMT2APDE5ATGFBR1
SCHEMBL27248472 0.76 ROCK2 (0.60) ABCG2MEN1KMT2ALMNATP53
SCHEMBL13154697 0.76 TGFBR1 (0.71) ABCG2MEN1KMT2APDE5ATGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED (GB) 2016-12-08 US claimed
US-20140031547-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED 2014-01-30 US claimed
EP-2651405-A2 CASEIN KINASE 1 (CK1 ) INHIBITORS Electrophoretics Limited (GB) 2013-10-23 EP claimed
WO-2012080729-A2 CASEIN KINASE 1δ (CK1δ) INHIBITORS ELECTROPHORETICS LIMITED (GB) 2012-06-21 WO claimed
US-20240000821-A1 CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER UNIV JOHNS HOPKINS (US) 2024-01-04 US disclosed
US-20200078387-A1 CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER THE JOHNS HOPKINS UNIVERSITY 2020-03-12 US disclosed
WO-2018112342-A1 CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER THE JOHNS HOPKINS UNIVERSITY (US) 2018-06-21 WO disclosed
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED (GB) 2016-12-08 US disclosed
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED (GB) 2016-12-08 US disclosed
US-20140031547-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED 2014-01-30 US disclosed
US-20140031547-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED 2014-01-30 US disclosed
EP-2651405-A2 CASEIN KINASE 1 (CK1 ) INHIBITORS Electrophoretics Limited (GB) 2013-10-23 EP disclosed
WO-2012080729-A2 CASEIN KINASE 1δ (CK1δ) INHIBITORS ELECTROPHORETICS LIMITED (GB) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031547-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES CSNK1G1, CSNK1A1, CSNK1G3 ABCG2 4649/4885MEN1 3661/4885KMT2A 1033/4885
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES CSNK1G1, CSNK1A1, CSNK1D ABCG2 4161/4885MEN1 3510/4885KMT2A 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.